|1.||Thomas, Astrid: 1 article (06/2010)|
|2.||Onofrj, Marco: 1 article (06/2010)|
|3.||Varanese, Sara: 1 article (06/2010)|
|4.||Bonanni, Laura: 1 article (06/2010)|
|5.||Monaco, Daniela: 1 article (06/2010)|
|6.||Tiraboschi, Pietro: 1 article (06/2010)|
|7.||Perfetti, Bernardo: 1 article (06/2010)|
|8.||Schibli, Roger: 1 article (04/2010)|
|9.||Leamon, Christopher P: 1 article (04/2010)|
|10.||Müller, Cristina: 1 article (04/2010)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
06/01/1988 - "Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer."
08/01/1988 - "The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid)."
|2.||T-Cell Leukemia (Leukemia, T Cell)
09/01/1997 - "TMQ was more potent against approximately 200-fold N10-propargyl-5,8-dideazafolic-acid (CB3717)-resistant human T-cell leukemia MOLT-3 sublines developed in PGA (MOLT-3/CB3717(200)-PGA) or leucovorin (MOLT-3/CB3717(200)-LV), as compared to the parent cells; MOLT-3/CB3717(200)-PGA and MOLT-3/CB3717(200)-LV cells were resistant to CB3717 by virtue of impaired transport, only the former possessing gene amplification of thymidylate synthase. "
|3.||Hepatocellular Carcinoma (Hepatoma)
06/01/1989 - "Transport studies in vitro established that DMPDDF effectively inhibits MTX influx into H35 hepatoma cells, whereas PDDF has no effect on MTX transport in this cell line. "
06/01/1987 - "Our results suggest that CB3717 will be a useful new therapeutic agent in hepatocellular carcinoma. "
06/01/1987 - "In a Phase II clinical trial, 14 consecutive, unselected patients with primary hepatocellular carcinoma were treated with a new inhibitor of thymidylate synthase, CB3717. "
02/01/1987 - "Serum vitamin B12 levels in patients with primary hepatocellular carcinoma during treatment with CB3717."
03/01/1986 - "Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717."
|5.||Breast Neoplasms (Breast Cancer)
04/01/1988 - "Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer."
04/01/1988 - "Fifty-two patients with progressive advanced breast cancer were treated with the novel antifolate CB 3717 (N10-propargyl-5,8-dideazofolic acid) which inhibits thymidylate synthetase. "
01/01/1987 - "In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma. "
|2.||Prostaglandins A (PGA)
|4.||Leucovorin (Folinic Acid)
|5.||Folic Acid Antagonists
|8.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|1.||Heterologous Transplantation (Xenotransplantation)